Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

NASDAQ: ONTX was devalued by  Zacks Research  from a “purchase” ranking to a “hold” rating in a research note issued to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on finding and also developing small molecule drug candidates to treat cancer. The Company‘s products under different stages of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research analysts additionally just recently discussed the business. Noble Financial reissued a “get” score as well as released a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating ordinary rate of $2.90 as well as a two-hundred day moving typical cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, topping analysts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as a negative net margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, compared to the agreement estimate of $0.06 million. During the exact same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly publish -1.18 EPS for the present year.

A number of hedge funds have actually lately dealt shares of ONTX. GSA Capital Partners LLP purchased a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Administration LP got a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional investors possess 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition as well as advancement of oncology therapeutics. It focuses on discovering and also creating little particle drug candidates to deal with cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a free copy of the Zacks research record on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, check out Zacks.com.

This instantaneous information alert was created by narrative scientific research technology as well as financial data from Market in order to give viewers with the fastest and also most exact coverage. This tale was evaluated by Market’s editorial group before publication. 



Before you think about Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s top-rated as well as ideal carrying out research analysts and the stocks they advise to their clients every day. Market has determined the five stocks that cover experts are silently murmuring to their clients to acquire currently prior to the wider market catches on … and Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics presently has a “Buy” ranking among analysts, top-rated analysts think these 5 stocks are much better acquires.